Colorectal Cancer Clinical Trial
— MOBILE2Official title:
Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial
Verified date | November 2022 |
Source | Helsinki University Central Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
MOBILE2 is a randomized controlled trial comparing mechanical and oral antibiotic bowel preparation to mechanical bowel preparation only in patients undergoing anterior rectal resection with primary anastomosis. Primary endpoint is Comprehensive Complication Index within 30 days from surgery.
Status | Active, not recruiting |
Enrollment | 604 |
Est. completion date | October 10, 2027 |
Est. primary completion date | November 9, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients scheduled for anterior rectal resection with primary anastomosis Exclusion Criteria: - Emergency operation - Bowel obstruction - Existing stoma - Other reason preventing mechanical bowel preparation - Allergy to neomycin or metronidazole - Age < 18 years - Lack of co-operation Exclusion criteria after randomization: - Patient did not undergo surgery - Anterior resection was not performed - Colonic anastomosis was not performed |
Country | Name | City | State |
---|---|---|---|
Finland | Helsinki University Hospital | Helsinki | |
Finland | Tampere University Hospital | Tampere | |
Finland | Turku University Hospital | Turku |
Lead Sponsor | Collaborator |
---|---|
Helsinki University Central Hospital |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 5-year overall survival | 5-year overall survival | 5 years from surgery | |
Other | 5-year disease specific survival | 5-year disease specific survival | 5 years from surgery | |
Other | 5-year recurrence free survival | 5-year recurrence free survival | 5 years from surgery | |
Other | Quality of life (SF-36) | Difference in quality of life between baseline and 1 year measured using SF-36 | At randomization and at one year from surgery | |
Other | Quality of life (QLQ-C30) | Difference in quality of life between baseline and 1 year measured using QLQ-C30 | At randomization and at one year from surgery | |
Other | Quality of life (QLQ-CR29) | Difference in quality of life between baseline and 1 year measured using QLQ-CR29 | At randomization and at one year from surgery | |
Other | Quality of life (LARS) | Difference in quality of life between baseline and 1 year measured using LARS | At randomization and at one year from surgery | |
Other | Adverse effects of antibiotics | Adverse effects of antibiotics | Within 30 days from surgery | |
Other | Bowel microbiota | Bowel microbiota | Before, at, 6 months, and 1 year after surgery. | |
Primary | Comprehensive Complication Index | Comprehensive Complication Index score | Within 30 days from surgery | |
Secondary | Surgical Site Infection | Surgical site infection as defined by CDC | Within 30 days from surgery | |
Secondary | Anastomotic dehiscence | Anastomotic dehiscence | Within 30 days from surgery | |
Secondary | Lenght of hospital stay | Lenght of hospital stay | Within hospital stay, estimated on average 7 days | |
Secondary | Mortality | Mortality | Within 90 days from surgery | |
Secondary | Adjuvant therapy | Patients receiving adjuvant therapy divided by patients needing adjuvant therapy | Within 6 months from surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |